[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neonatal-hypoxic-ischemic-encephalopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neonatal-hypoxic-ischemic-encephalopathy":62},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,76,112,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100651183","continuous-monitoring-of-body-temperature-in-neonates-during-therapeutic-hypothermia-100651183",false,"NCT07756892","Continuous Monitoring of Body Temperature in Neonates During Therapeutic Hypothermia","Continuous Monitoring of Body Temperature in Neonates During Therapeutic Hypothermia - A Prospective Observational Pilot Study","MonT HT","Inclusion Criteria:\n\n* Neonates born at ≥36+0 weeks of gestation.\n* Clinical indication for therapeutic hypothermia.\n* Written informed consent obtained from the parents or legal guardians before study measurements are initiated.\n\nExclusion Criteria:\n\n* Gestational age \\\u003C36+0 weeks.\n* No clinical indication for therapeutic hypothermia.\n* Written informed consent not obtained from the parents or legal guardians.\n* Congenital malformation.","ALL","3 Days","1 Week",{"count":21,"type":22},10,"ESTIMATED","OBSERVATIONAL","This prospective observational pilot study aims to evaluate the feasibility, accuracy, and safety of the SteadyTemp® wireless adhesive thermometer for continuous, non-invasive body temperature monitoring in neonates undergoing therapeutic hypothermia following hypoxic-ischemic encephalopathy. Currently, body temperature during therapeutic hypothermia is monitored using an invasive rectal temperature probe, which carries risks such as tissue injury, perforation, infection, and patient discomfort.\n\nThe study will enroll ten neonates born at ≥36 weeks of gestation who require therapeutic hypothermia. During the rewarming phase of treatment, the SteadyTemp® adhesive thermometer will be applied to the right axillary area for approximately 10 hours while routine rectal temperature monitoring continues. Temperature measurements obtained with the adhesive thermometer will be compared with simultaneous rectal core temperature measurements. In addition, skin condition after removal of the adhesive patch will be assessed using the Neonatal Skin Condition Scale (NSCS) to evaluate local tolerability.\n\nThe study seeks to answer the following research questions:\n\nCan the SteadyTemp® adhesive thermometer continuously and reliably monitor body temperature in neonates during therapeutic hypothermia? Do temperature measurements obtained with the non-invasive adhesive thermometer show sufficient agreement with standard invasive rectal temperature measurements, including temperatures below 36°C? Is prolonged application of the adhesive thermometer safe and well tolerated, without causing clinically relevant skin irritation?\n\nThe findings from this pilot study will provide preliminary evidence on the feasibility and agreement of this non-invasive monitoring method and will inform the design of larger validation studies investigating whether the SteadyTemp® adhesive thermometer could serve as a safe alternative to invasive rectal temperature monitoring during therapeutic hypothermia in neonates.",[26,27,28],"Therapeutic Hypothermia","Neonatal Hypoxic-Ischemic Encephalopathy","Neonatal Thermal Management",[30,31,32],"continous temperature measurement","neonate","hypothermia","NOT_YET_RECRUITING","2026-08-05",{"date":36,"type":37},"2026-08-11","ACTUAL",{"date":39,"type":22},"2026-08-15",{"date":41,"type":22},"2028-08-15",{"name":43,"class":44},"Medical University of Graz","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100489107","phase-3-neonatal-brain-ultrasound-with-ceus-and-elastography-100489107","NCT05648812","Neonatal Brain Ultrasound With CEUS and Elastography","Contrast Enhanced Ultrasound and Elastography of the Neonatal Brain","Inclusion Criteria:\n\n* Babies less than 7 months treated at the neonatal units of Turku University hospital\n\nExclusion Criteria:\n\n* Pre-known genetic disease\n* Difficult congenital malformations that need surgical treatment\n* Central nervous system tumors\n* Weight less than 2,5 kg during examination\n* Medical history of SonoVue hypersensitivity\n* Uncontrolled systemic hypertension\n* Systolic pulmonary artery pressure \\> 90 mmHg\n* Unstable cardiovascular state","1 Minute","6 Months",{"count":56,"type":22},100,"INTERVENTIONAL",[59],"PHASE3","The aim of our study is to investigate changes of brain perfusion and elasticity in neonates during the time that a neonate is adapting to live outside the womb and during diseases that are suspected to affect neonatal brain perfusion. We use contrast enhanced ultrasound (sulphur hexafluoride) and ultrasound-assisted elastography to evaluate the state of brain perfusion. We will study neonates recruited from the Neonatal Units of Turku University Hospital.",[62,63,64],"Neonatal Hypoxic Ischemic Encephalopathy","Neonatal Stroke","Neonatal Encephalopathy, Unspecified","RECRUITING","2026-01-13",{"date":68,"type":37},"2026-01-15",{"date":70,"type":37},"2024-01-01",{"date":72,"type":22},"2029-12",{"name":74,"class":75},"Turku University Hospital","OTHER_GOV",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":57,"phases":86,"briefSummary":88,"conditions":89,"keywords":96,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":45},"100573513","early-phase-1-feasibility-and-safety-of-intranasally-administered-breast-milk-in-hie-100573513","NCT06747260","Feasibility and Safety of Intranasally Administered Breast Milk in HIE","Feasibility and Safety of Intranasal Breast Milk in Hypoxic-ischaemic Encephalopathy","F-NEO-BRIGHT","Inclusion Criteria:\n\n* Moderate or severe hypoxic- ischaemic encephalopathy, receiving therapeutic hypothermia\n* ≥ 35. gestational week\n* \\\u003C 48 hours of life\n* Hypothermia treatment for 72 hours\n* Parental consent form\n\nExclusion Criteria:\n\n* Congenital malformation\n* Concurrent cerebral lesions\n* ECMO therapy\n* Contraindication of lactation\n* Mother unable or unwilling to provide fresh breast milk\n* Postpartum asphyxia","48 Hours",{"count":21,"type":22},[87],"EARLY_PHASE1","This is a prospective intervention single center study to evaluate the feasibility and safety of intranasal breast milk in hypoxic-ischaemic encephalopathic neonates receiving therapeutic hypothermia.",[90,91,92,62,93,94,95],"Hypoxic Ischaemic Encephalopathy (HIE)","Hypoxic Ischemic Encephalopathy of Newborn","Neonatal Encephalopathy","Brain Injury","Perinatal Asphyxia","Perinatal Asphyxia , Moderate to Severe HIE",[97,98,99,100,101,102],"Hypoxic-ischaemic encephalopathy","Neonatal encephalopathy","Perinatal asphyxia","Breast milk","Breast milk stem cells","Intranasal breast milk","2025-05-19",{"date":105,"type":37},"2025-05-22",{"date":107,"type":37},"2024-11-22",{"date":109,"type":22},"2030-01-01",{"name":111,"class":44},"Semmelweis University",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":84,"enrollmentInfo":120,"targetDuration":4,"studyType":57,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":45},"100573457","early-phase-1-intranasal-breast-milk-therapy-in-hie-100573457","NCT06746532","Intranasal Breast Milk Therapy in HIE","Neonatal Intranasal Breast Milk, Impact on Brain Growth in Hypoxic-ischemic Encephalopathy Therapy (NEO-BRIGHT)","NEO-BRIGHT","Inclusion Criteria:\n\n* Moderate or severe hypoxic- ischemic encephalopathy, receiving therapeutic hypothermia\n\n  ≥ 35. gestational week \\\u003C 48 hours of life\n* Hypothermia treatment for 72 hours\n* Parental consent form\n\nExclusion Criteria:\n\n* Congenital malformation\n* Concurrent cerebral lesions\n* ECMO therapy\n* Contraindication of lactation\n* Mother unable or unwilling to provide fresh breast milk\n* Postpartum asphyxia",{"count":121,"type":22},80,[87],"This is an open-label prospective single-center randomized controlled trial to evaluate the effect of intranasal breast milk in hypoxic-ischemic encephalopathic neonates receiving therapeutic hypothermia on long term neurodevelopmental outcome compared to standard care.",[125,92,94,62],"Hypoxic-Ischaemic Encephalopathy",[127,128,129,130,131,132],"HIE","intranasal breast milk","perinatal asphyxia","brain","breast milk stem cells","hypoxic-ischemic encephalopathy","2024-12-20",{"date":135,"type":37},"2024-12-24",{"date":137,"type":22},"2025-02-01",{"date":139,"type":22},"2030-12",{"name":111,"class":44},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":57,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100561437","early-phase-1-erythropoietin-in-hie-neonate-100561437","NCT06590155","Erythropoietin in HIE Neonate","Role of Erythropoietin in Neonates With Hypoxic Ischemic Encephalopathy","Inclusion Criteria:\n\n\\- neonates who less than 1 month suffer from hypoxic ischemic encephalopathy\n\nExclusion Criteria:\n\n* neonates who more than 1 month\n* neonates who suffer from brain insults other than HIE","1 Day","1 Month",{"count":151,"type":22},3,[87],"this study is aim to delineate the role of erythropoietin in improving neonatal hypoxic ischemic encephalopathy the study is conducted to answer the question : is erythropoietin will improve neonatal hypoxic ischemic encephalopathy?",[62],"2024-09-06",{"date":157,"type":37},"2024-09-19",{"date":159,"type":22},"2024-11-24",{"date":161,"type":22},"2029-02-24",{"name":163,"class":44},"Assiut University"]